Cancers, Vol. 12, Pages 897: Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
Conclusions: The association of sorafenib does not prolong survival nor delay progression in patients treated with radioembolization. Liver toxicity does not differ among the two therapeutic schemes.
Source: Cancers - Category: Cancer & Oncology Authors: Antonio Facciorusso Irene Bargellini Marina Cela Ivan Cincione Rodolfo Sacco Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Toxicology | Urology & Nephrology